Papillomavirus Infections
📧 Sign up to get email alerts when something new happens for Papillomavirus Infections.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2026-07-09EMA Authorised: Cervarix (human papillomavirus1 type 16 L1 protein;human papillomavirus type 18 L1 protein) — GlaxoSmithKline Biologicals S.A.
Cervarix, a vaccine targeting HPV types 16 and 18, has been authorised by the EMA for use in immunization against papillomavirus infections …
-
CLINICAL_TRIALS trial_result · 2026-06-02Clinical Trial Update: Efficacy, Immunogenicity and Safety of V503 in Chinese Women Aged 20-45 Years (V503-023) [Phase 3]
Phase 3 trial update on V503 evaluating efficacy, immunogenicity, and safety in Chinese women aged 20-45 with papillomavirus infections.
-
CLINICAL_TRIALS trial_result · 2024-12-16Clinical Trial Update: Efficacy, Immunogenicity, and Safety of V503 in Chinese Males (V503-052) [Phase 3]
This Phase 3 trial update evaluates the efficacy, immunogenicity, and safety of the V503 vaccine in Chinese males with papillomavirus infect…
-
CLINICAL_TRIALS trial_result · 2024-06-03Clinical Trial Update: ALA-PDT in Patients With CIN2 in p16-positivity and High-risk HPV Infection [Phase 2]
Phase 2 trial evaluating 5-aminolevulinic acid–based photodynamic therapy (ALA-PDT) in CIN2 patients who are p16-positive and HPV high-risk …
-
CLINICAL_TRIALS trial_result · 2023-12-13Clinical Trial Update: The KEN SHE Study on HPV-vaccine Efficacy [Phase 4]
Phase 4 clinical trial update on the KEN SHE study evaluating HPV-vaccine efficacy for papillomavirus infections.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2022-11-16Clinical Trial Update: Efficacy, Immunogenicity and Safety of V503 in Chinese Women Aged 20-45 Years (V503-023) [Phase 3]
Phase 3 trial update on efficacy, immunogenicity, and safety of V503 in Chinese women aged 20-45 with papillomavirus infection.
-
CLINICAL_TRIALS trial_result · 2022-10-28Clinical Trial Update: Phase III Study Comparing the Immunogenicity of 9-valent HPV Recombinant Vaccine and Gardasil-9 [Phase 3]
Phase III study comparing immunogenicity of a 9-valent HPV recombinant vaccine with Gardasil-9; status is UNKNOWN.
-
CLINICAL_TRIALS trial_result · 2022-09-02Clinical Trial Update: V503 in Chinese Girls 9-14 Years Old Versus Chinese Women 20-26 Years Old (V503-071) [Phase 3]
Phase 3 trial update comparing V503 in Chinese girls 9-14 with Chinese women 20-26 for papillomavirus infections; study status is ACTIVE_NOT…
-
CLINICAL_TRIALS trial_result · 2022-02-01Clinical Trial Update: E7 TCR Cell Induction Immunotherapy for Stage II and Stage III HPV-Associated Oropharyngeal Cancer [Phase 2]
Phase 2 trial update for E7 TCR cell induction immunotherapy in stage II/III HPV-associated oropharyngeal cancer; trial terminated with resu…
-
CLINICAL_TRIALS trial_result · 2020-02-05Clinical Trial Update: Safety and Immunogenicity Study of V503 (GARDASIL™9, 9vHPV Vaccine) Administered to 9- to 26-Year-Old Females and Males in Vietnam (V503-017) [Phase 3]
Phase 3 safety and immunogenicity study of GARDASIL 9 (V503) in 9- to 26-year-old females and males in Vietnam has completed enrollment with…
-
CLINICAL_TRIALS trial_result · 2019-07-08Clinical Trial Update: Aminolaevulinic Acid Photodynamic Therapy for HPV+ Low Grade Cervical Intraepithelial Neoplasia (LSIL;CIN1) [Phase 2]
Phase 2 clinical trial investigating aminolevulinic acid photodynamic therapy for HPV-positive low-grade cervical intraepithelial neoplasia …
-
CLINICAL_TRIALS trial_result · 2019-07-02Clinical Trial Update: Evaluation of the Effectiveness of an Alcohol Based Hand Gel for the Reduction of Warts on the Hands [NA]
A completed clinical trial evaluated the effectiveness of an alcohol-based hand gel for reducing warts on the hands; results were posted in …
-
CLINICAL_TRIALS trial_result · 2019-05-22Clinical Trial Update: Efficacy of VIUSID® Plus GLIZIGEN® in Patients With Papilloma Virus Esophageal [Phase 2]
Phase 2 trial assessing VIUSID® Plus GLIZIGEN® for papillomavirus-related esophageal conditions has completed.
-
EMA withdrawal · 2019-04-02EMA Withdrawn: Silgard (human papillomavirus type 6 L1 protein;human papillomavirus type 11 L1 protein;human papillomavirus type 16 L1 protein;human papillomavirus type 18 L1 protein) — Merck Sharp Dohme Ltd
EMA withdrawn the HPV vaccine Silgard (HPV 6/11/16/18 L1 proteins) from the market.
-
CLINICAL_TRIALS research · 2018-10-17Clinical Trial Update: Gynaecological Follow-up of a Subset of HPV-015 (NCT00294047) Study Subjects [Phase 3]
A Phase 3 clinical trial update for a subset of HPV-015 study subjects focusing on gynecologic follow-up; results have been posted.
-
CLINICAL_TRIALS trial_result · 2018-10-12Clinical Trial Update: Impact of AV2 Antiviral Drug on the Treatment of HPV-associated Lesions of the Uterine Cervix [Phase 3]
Phase 3 trial update on AV2 antiviral drug for HPV-associated cervical lesions showing completed status.
-
CLINICAL_TRIALS trial_result · 2018-09-17Clinical Trial Update: Evaluation of the Immunogenicity and Safety of GlaxoSmithKline Biologicals' HPV Vaccine in Young Males. [Phase 2]
Phase 2 trial evaluating immunogenicity and safety of GlaxoSmithKline's HPV vaccine in young males has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2014-12-22Clinical Trial Update: A Study of V503 Vaccine Given Concomitantly With REPEVAX™ in 11 to 15 Year Olds (V503-007) [Phase 3]
Phase 3 study evaluating V503 vaccine given with REPEVAX in 11- to 15-year-olds completed; results posted in 2014 for papillomavirus infecti…
-
CLINICAL_TRIALS trial_result · 2014-12-22Clinical Trial Update: A Study of the Safety, Tolerability, and Immunogenicity of a 9-valent Human Papillomavirus Vaccine ([9vHPV]; V503) Administered to 9- to 15-Year-Old Japanese Girls (V503-008). [Phase 3]
A phase 3 trial assessing safety, tolerability, and immunogenicity of 9-valent HPV vaccine (V503) in Japanese girls aged 9-15; trial complet…
-
CLINICAL_TRIALS trial_result · 2014-06-03Clinical Trial Update: GARDASIL™ Study in Healthy Females Between 9 and 26 Years of Age in Sub-Saharan Africa (V501-046) [Phase 3]
Phase 3 clinical trial update for GARDASIL in healthy females aged 9-26 in Sub-Saharan Africa, with completed status and posted results.
-
CLINICAL_TRIALS trial_result · 2013-12-05Clinical Trial Update: Evaluation of Immunogenicity and Safety of Two 2-dose Human Papillomavirus (HPV) Vaccine Schedules in 9-14 Year Old Girls [Phase 3]
Phase 3 trial evaluating immunogenicity and safety of two two-dose HPV vaccine schedules in girls aged 9-14; results posted after completion…
-
CLINICAL_TRIALS trial_result · 2013-12-03Clinical Trial Update: Study to Assess Immune Responses and Safety of the GSK-580299 Vaccine in Healthy Women (26 to 45 Years) [Phase 3]
Phase 3 trial update for the GSK-580299 vaccine in healthy women; study completed with results posted in 2013.
-
CLINICAL_TRIALS trial_result · 2012-06-27Clinical Trial Update: Immunogenicity and Safety Study of GSK Biologicals' Human Papillomavirus 580299 Vaccine in Healthy Female Subjects [Phase 3]
Phase 3 immunogenicity and safety study of GSK HPV vaccine in healthy female subjects has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2012-05-10Clinical Trial Update: Efficacy, Immunogenicity and Safety of GSK Biologicals' HPV GSK 580299 Vaccine in Healthy Chinese Female Subjects [Phase 3]
A Phase 3 trial update reporting on the efficacy, immunogenicity, and safety of GSK's HPV vaccine (GSK 580299) in healthy Chinese female sub…
-
CLINICAL_TRIALS trial_result · 2012-03-27Clinical Trial Update: Study to Evaluate the Efficacy of the Human Papillomavirus Vaccine in Healthy Adult Women of 26 Years of Age and Older [Phase 3]
Phase 3 clinical trial update for the HPV vaccine in healthy adult women aged 26 and older; study completed with results posted in 2012.